Mirabegron 50mg Tablet is a prescription beta-3 adrenergic receptor agonist used to treat symptoms of overactive bladder (OAB), including urinary urgency, increased urinary frequency and urge urinary incontinence. In the USA, mirabegron is marketed as Myrbetriq®, while Betmiga® is a major brand reference in markets including the UK and Australia. Generic mirabegron extended-release 50mg tablets are also FDA-approved in the United States.
Mirabegron works differently from traditional antimuscarinic bladder medicines by stimulating beta-3 adrenergic receptors in the bladder, helping the bladder muscle relax and increasing its storage capacity.
Mirabegron 50mg is used to manage symptoms associated with overactive bladder (OAB).
These symptoms may include:
The FDA-approved US labeling identifies mirabegron as a beta-3 adrenergic agonist indicated for adult OAB with urgency, urinary frequency and urge urinary incontinence.
Mirabegron 50mg for overactive bladder is the core commercial and clinical search relationship for this product.
Mirabegron relaxes the detrusor smooth muscle during the bladder filling phase, allowing the bladder to store more urine and reducing urgency and frequency.
The NHS describes mirabegron as a medicine that relaxes the muscles around the bladder, increasing the amount of urine the bladder can hold.
Urinary urgency is one of the primary symptoms associated with overactive bladder.
By activating beta-3 receptors in the bladder, mirabegron can help reduce involuntary bladder contractions and improve the ability to postpone urination.
Patients with overactive bladder may experience urinary frequency, sometimes accompanied by urgency or urge incontinence.
Mirabegron is specifically indicated for OAB symptoms involving increased urinary frequency.
Mirabegron for urge urinary incontinence is another high-intent indication keyword.
Urge urinary incontinence occurs when a strong, sudden need to urinate results in involuntary urine leakage. Mirabegron may help by improving bladder storage and reducing involuntary detrusor activity.
Mirabegron is a beta-3 adrenergic receptor agonist.
It activates beta-3 receptors in the detrusor muscle of the bladder. This promotes relaxation during bladder filling, allowing the bladder to store a greater volume of urine.
Unlike antimuscarinic medicines, mirabegron does not primarily work through muscarinic receptor blockade. This different mechanism makes it an important pharmacological option for patients with OAB when antimuscarinic treatment is unsuitable, ineffective or poorly tolerated.
Myrbetriq® is a brand name for mirabegron.
Generic mirabegron contains the same active ingredient, although inactive ingredients, manufacturer, packaging and regulatory status can differ between products.
In the United States, FDA-approved generic mirabegron extended-release tablets are available in both 25mg and 50mg strengths.
Important: The phrase “Generic Myrbetriq” should be used for a specific product only where its regulatory status supports that description in the relevant market.
Betmiga® is another major brand reference for mirabegron and is used in markets such as the UK and Australia.
The Australian TGA lists Betmiga mirabegron 50mg prolonged-release tablets as a registered prescription medicine.
For SEO and product categorization, commercially relevant relationships include:
Mirabegron 50mg → Generic Myrbetriq 50mg → Mirabegron Extended-Release 50mg → Betmiga 50mg
Mirabegron is available in 25mg and 50mg extended-release tablets. In the US prescribing information, the recommended starting dose for adult OAB is 25mg once daily, with an increase to 50mg once daily based on individual efficacy and tolerability.
In the UK, NHS guidance states that the usual dose is 50mg once daily, while 25mg may be recommended for some patients with kidney or liver problems.
The appropriate strength depends on the patient’s medical history, kidney and liver function, concurrent medicines and prescriber’s assessment.
Mirabegron extended-release tablets are generally taken orally once daily according to the prescribed regimen.
The extended-release tablet should be swallowed whole rather than chewed, divided or crushed.
Patients should follow the instructions supplied with their specific product and prescription.
Potential adverse effects include:
The FDA labeling identifies hypertension, nasopharyngitis, urinary tract infection and headache among commonly reported adverse reactions.
The Australian product information similarly reports hypertension, urinary tract infection and headache among observed adverse events.
Mirabegron can increase blood pressure.
Blood pressure should be assessed before treatment and monitored according to clinical circumstances, particularly in patients with hypertension. Mirabegron is not recommended in patients with severe uncontrolled hypertension.
Patients with high blood pressure should discuss mirabegron with their healthcare professional before starting treatment.
Mirabegron should be used with caution in patients with bladder outlet obstruction or in patients taking certain antimuscarinic medicines because of the potential risk of urinary retention.
Mirabegron can interact with certain medicines.
Of particular importance, mirabegron is a moderate CYP2D6 inhibitor, which may increase exposure to medicines metabolized through CYP2D6. Appropriate monitoring or dose adjustment may be required for some medicines with a narrow therapeutic index.
Tell your healthcare professional about all prescription medicines, over-the-counter medicines and supplements you use.
Kidney function can affect the appropriate mirabegron dose.
Patients with significant renal impairment may require a lower dose, and some severe renal impairment situations may limit use. The precise dose depends on renal function and the product’s prescribing information.
Patients with liver impairment may require a reduced dose or may not be suitable for mirabegron depending on the severity of hepatic impairment.
Patients should disclose known liver disease before treatment.
Mirabegron 50mg Tablet has strong commercial search intent around overactive bladder treatment and generic alternatives to Myrbetriq®.
High-intent product searches include:
Mirabegron 50mg Tablet, Mirabegron 50mg Extended Release, Mirabegron 50mg Tablets, Generic Myrbetriq 50mg, Myrbetriq 50mg Generic, Mirabegron 50mg for Overactive Bladder, Mirabegron 50mg for Urinary Urgency, Mirabegron 50mg for Urge Incontinence, Mirabegron 50mg Price and Mirabegron 50mg Online.
Generic mirabegron 50mg products have FDA approvals in the United States, with multiple manufacturers listed as having approved products and several having entered the US market.
Prescription status, manufacturer availability, approved indications and import requirements vary by country.
Mirabegron 50mg is used to treat symptoms of overactive bladder, including urinary urgency, increased urinary frequency and urge urinary incontinence.
Myrbetriq® is a brand-name mirabegron product. Generic mirabegron contains the same active ingredient, but the manufacturer and inactive ingredients may differ.
Yes. FDA-approved generic mirabegron extended-release tablets are available in 25mg and 50mg strengths in the United States.
Betmiga® is a brand reference for mirabegron used in several international markets. A specific generic product should be described as equivalent to the relevant reference product only where its regulatory status supports that claim.
It treats symptoms associated with overactive bladder, including urgency, frequency and urge urinary incontinence.
Mirabegron activates beta-3 adrenergic receptors in the bladder, relaxing the detrusor muscle and increasing bladder storage capacity.
No. Mirabegron is a bladder medicine, not an antihypertensive. It can actually increase blood pressure, which is why blood-pressure monitoring is important during treatment.
Yes. Mirabegron 25mg and 50mg prolonged-release tablets are used in UK clinical practice for overactive bladder, and Betmiga® is a recognized brand reference.
Mirabegron may be used long term when clinically appropriate. NHS guidance notes that many patients use it for months or years under medical supervision.
Yes. Mirabegron is a prescription medicine.
Both are extended-release strengths. The appropriate strength depends on the patient’s condition, response, tolerability and kidney or liver function.
In the United States, Myrbetriq is indicated for adult OAB both alone and in combination with solifenacin. Combination treatment should only be used when prescribed by an appropriate healthcare professional.
Mirabegron starts acting within several hours, but noticeable improvement in OAB symptoms can take several weeks. NHS guidance notes that full benefit may take around 4–8 weeks.
Medical Disclaimer: This product information is provided for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Mirabegron is a prescription medicine and should be used according to the prescribing information applicable to the specific product and country. It can increase blood pressure and may cause urinary retention in susceptible patients. Always consult a qualified healthcare professional before starting, stopping or changing treatment.
Last Updated: August 25, 2026
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
Mirabegron 50mg Tablet
Reviews
There are no reviews yet